Jasper Therapeutics, Inc. filed a Form S-3 registration statement with the SEC on October 14, 2026, covering the potential resale of up to 284,013,011 shares of common stock by selling stockholders following conversion of preferred stock issued in a July 2026 private placement.
Key Highlights
- Resale shares registered: Up to 284,013,011 shares of common stock, par value $0.0001 per share, are covered by the prospectus.
- Source of shares: The shares are issuable upon conversion of 4,655,951 shares of non-voting convertible preferred stock issued in a private placement under a securities purchase agreement dated July 16, 2026.
- Conversion ratio: Each share of PIPE Preferred Stock will automatically convert into 61 shares of common stock, subject to beneficial ownership limitations, on the third business day following receipt of stockholder approval.
- No proceeds to company: Jasper Therapeutics will not receive any proceeds from the sale of the resale shares; all proceeds will go to the selling stockholders.
- Last reported share price: The last reported sale price of common stock on October 13, 2026, was $0.4956 per share, according to the filing.
- Filer status: The company is classified as a non-accelerated filer and a smaller reporting company as defined under Rule 12b-2 of the Exchange Act.
Jasper Therapeutics Registers PIPE Conversion Shares for Resale After July 2026 Private Placement
According to the filing, Jasper Therapeutics (NASDAQ:JSPR) submitted a shelf registration statement on Form S-3 to allow selling stockholders to resell up to 284,013,011 shares of common stock. Those shares are issuable upon the conversion of 4,655,951 shares of non-voting convertible preferred stock, par value $0.0001 per share, that were issued to certain investors in a private placement pursuant to a securities purchase agreement dated July 16, 2026. The company described these as "PIPE Preferred Stock."
The filing states that each share of PIPE Preferred Stock will automatically convert into 61 shares of common stock, subject to beneficial ownership limitations, on the third business day following receipt of stockholder approval of, among other things, the issuance of shares of common stock upon conversion of the preferred stock. The registration statement was filed on a delayed or continuous basis under Rule 415 of the Securities Act of 1933. The company noted it will bear all costs, expenses, and fees in connection with the registration, while the selling stockholders will bear any commissions or discounts attributable to their respective sales.
Jasper Therapeutics disclosed it is not offering any shares for its own account through this prospectus and will receive no proceeds from any resale transactions. The registration of the resale shares does not obligate the selling stockholders to sell. The common stock is listed on the Nasdaq Capital Market under the symbol "JSPR," and the filing noted the last reported sale price of $0.4956 per share as of October 13, 2026. The company identified itself as a smaller reporting company and noted it has elected to comply with certain reduced public company reporting requirements.
What Was Disclosed
Jasper Therapeutics filed a Form S-3 on October 14, 2026, registering up to 284,013,011 common shares for resale by selling stockholders. The shares stem from 4,655,951 preferred shares issued in a July 16, 2026 private placement, each convertible into 61 common shares upon stockholder approval.




Please wait processing your request...